These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells. Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756 [TBL] [Abstract][Full Text] [Related]
11. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors. Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196 [TBL] [Abstract][Full Text] [Related]
12. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors. Hsieh CL; Yang L; Miao L; Yeung F; Kao C; Yang H; Zhau HE; Chung LW Cancer Res; 2002 Jun; 62(11):3084-92. PubMed ID: 12036918 [TBL] [Abstract][Full Text] [Related]
13. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044 [TBL] [Abstract][Full Text] [Related]
14. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas. Kaliberov SA; Kaliberova LN; Buchsbaum DJ Gene Ther; 2005 Mar; 12(5):407-17. PubMed ID: 15616600 [TBL] [Abstract][Full Text] [Related]
15. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652 [TBL] [Abstract][Full Text] [Related]
16. Gene therapy for prostate cancer: where are we now? Steiner MS; Gingrich JR J Urol; 2000 Oct; 164(4):1121-36. PubMed ID: 10992352 [TBL] [Abstract][Full Text] [Related]
17. Biological principles and clinical development of prostate cancer gene therapy. Sanda MG Semin Urol Oncol; 1997 Feb; 15(1):43-55. PubMed ID: 9050139 [TBL] [Abstract][Full Text] [Related]
18. The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate? Marignol L; Robson T; McCarthy HO; Worthington J; Murray MM; Hollywood D; Lawler M; Hirst DG J Gene Med; 2008 Sep; 10(9):1032-8. PubMed ID: 18615772 [TBL] [Abstract][Full Text] [Related]
19. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Pramudji C; Shimura S; Ebara S; Yang G; Wang J; Ren C; Yuan Y; Tahir SA; Timme TL; Thompson TC Clin Cancer Res; 2001 Dec; 7(12):4272-9. PubMed ID: 11751529 [TBL] [Abstract][Full Text] [Related]
20. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer. McCarthy HO; Coulter JA; Worthington J; Robson T; Hirst DG J Gene Med; 2007 Jun; 9(6):511-20. PubMed ID: 17471586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]